Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-20122 Combined Therapy in Advanced NSCLC
NCT07645222Phase 1Recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Jun 2026
- Primary completion
- Oct 2028
- Countries
- 1
01
Overview
Phase 1, open-label trial of HS-20122 in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Hansoh Pharmaceutical Group. Primary endpoints: Recommended Phase 2 Dose for Combination at 2 years, Objective Response Rate at 2 years and 3 more. Started Jun 2026; status: recruiting.
02
Drugs
HS-20122
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07645222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07645222.